Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Phil A. Hart

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4346-6196; OpenAlex author ID A5012767113. Sources: OpenAlex.

Their work

Papers
31 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
109
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 7 papers · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 6 papers

Papers 31

  1. Pancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the PRECEDE Consortium. Co-author DOI 10.1002/ijc.70592↗
  2. Diabetes secondary to chronic pancreatitis and pancreatic cancer: Observations from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancrea… Co-author DOI 10.1016/j.pan.2026.04.001↗
  3. Towards early detection of pancreatic cancer: The current status of cohort studies by the Diabetes-Pancreatic Ductal AdenoCarcinoma Working Group. Co-author DOI 10.1016/j.pan.2026.04.020↗
  4. Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study. Co-author DOI 10.1053/j.gastro.2025.06.025↗
  5. Adult Chronic Pancreatitis Working Group: Goals, Accomplishments and the Path Ahead. A Report From the Consortium for the Study of Chronic Pancreatitis, Diabet… Co-author DOI 10.1097/mpa.0000000000002657↗
  6. Assessment of impending pancreatic cancer in a cohort of new onset diabetes on basis of biomarker trajectory Co-author DOI 10.64898/2026.08.06.26359908↗
  7. Pancreatic cancer-related diabetes and type 2 diabetes differ in multiple aspects of glucose homeostasis. Last author DOI 10.1007/s00125-025-06543-y↗
  8. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  9. Fat malabsorption in pancreatic cancer: Pathophysiology and management. Co-author DOI 10.1002/ncp.11129↗
  10. Rising Incidence of Pancreatic Cancer in Patients 20 to 39 Years: A Population-Based Observational Study. Co-author DOI 10.1097/mpa.0000000000002231↗
  11. Differential Expression and Diagnostic Value of MUC5AC Glycoforms in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15194832↗
  12. Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer. First author DOI 10.3390/cells11050910↗
  13. Dietary Patterns of Insulinemia, Inflammation and Glycemia, and Pancreatic Cancer Risk: Findings from the Women's Health Initiative. First author DOI 10.1158/1055-9965.epi-20-1478↗
  14. Early detection of pancreatic cancer. Co-author DOI 10.1016/s2468-1253(19)30416-9↗
  15. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Last author DOI 10.1016/j.pan.2018.11.002↗
  16. Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.09.009↗
  17. Early Detection of Pancreatic Cancer in High-Risk Individuals: Where Do We Go From Here? Co-author DOI 10.14309/ajg.0000000000000192↗
  18. Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. Co-author DOI 10.1002/jcsm.12251↗
  19. Is Screening for Pancreatic Cancer in High-Risk Individuals One Step Closer or a Fool’s Errand? Co-author DOI 10.1016/j.cgh.2018.09.024↗
  20. Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. Co-author DOI 10.1016/j.jand.2017.07.005↗
  21. Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rational… Co-author DOI 10.1097/mpa.0000000000001168↗
  22. A Prospective Study to Establish a New-Onset Diabetes Cohort: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001169↗
  23. PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies: Rationale and Study Design for PROCEED From the Consortium for the … Co-author DOI 10.1097/mpa.0000000000001170↗
  24. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pan… Co-author DOI 10.1097/mpa.0000000000001171↗
  25. Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. Last author DOI 10.1097/mpa.0000000000000898↗
  26. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Co-author DOI 10.1016/s2468-1253(16)30106-6↗
  27. Impact of Intratumoral Inflammation on Survival After Pancreatic Cancer Resection. Co-author DOI 10.1097/mpa.0000000000000423↗
  28. Serum IgG4 elevation in pancreatic cancer: diagnostic and prognostic significance and association with autoimmune pancreatitis. Co-author DOI 10.1097/mpa.0000000000000297↗
  29. Impact of diabetes mellitus on clinical outcomes in patients undergoing surgical resection for pancreatic cancer: a retrospective, cohort study. Co-author DOI 10.1038/ajg.2014.193↗
  30. Diabetes mellitus and pancreatic cancer: why the association matters? Co-author DOI 10.1097/mpa.0b013e3182a7c963↗
  31. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Co-author DOI 10.1097/mpa.0b013e318220816a↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Suresh T. Chari · 12 shared papers, 2011–2026 · strength 1.35
  2. Stephen Jacob Pandol · 9 shared papers, 2016–2026 · strength 1.13
  3. Walter Gwang-Up Park · 6 shared papers, 2018–2026 · strength 1.05
  4. Dhiraj Yadav · 7 shared papers, 2016–2026 · strength 0.91
  5. Zobeida Cruz‐Monserrate · 9 shared papers, 2016–2026 · strength 0.89
  6. Dana K. Andersen · 6 shared papers, 2016–2026 · strength 0.87
  7. Christopher E Forsmark · 5 shared papers, 2016–2026 · strength 0.83
  8. Darwin Lewis Conwell · 8 shared papers, 2017–2026 · strength 0.82
  9. Melena D. Bellin · 5 shared papers, 2016–2026 · strength 0.79
  10. Evan L Fogel · 4 shared papers, 2018–2026 · strength 0.78
  11. Anirban Maitra · 4 shared papers, 2018–2026 · strength 0.76
  12. Randall E. Brand · 4 shared papers, 2018–2026 · strength 0.76
  13. Jo Ann Rinaudo · 6 shared papers, 2018–2026 · strength 0.71
  14. William E Fisher · 3 shared papers, 2026 · strength 0.71
  15. Santhi Swaroop Vege · 3 shared papers, 2026 · strength 0.69
  16. José Serrano · 6 shared papers, 2018–2026 · strength 0.68
  17. Mark Goodarzi · 5 shared papers, 2016–2026 · strength 0.64
  18. Ziding Feng · 5 shared papers, 2018–2026 · strength 0.63
  19. Mitchell L. Ramsey · 4 shared papers, 2018–2024 · strength 0.58
  20. Yogish C. Kudva · 4 shared papers, 2016–2026 · strength 0.56
  21. Bechien U. Wu · 2 shared papers, 2026 · strength 0.45
  22. Frederico G. S. Toledo · 2 shared papers, 2025–2026 · strength 0.45
  23. Kenneth Cusi · 2 shared papers, 2025–2026 · strength 0.45
  24. Steven J. Hughes · 4 shared papers, 2018–2026 · strength 0.43
  25. Mark D. Topazian · 3 shared papers, 2018–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.